Jeito Capital
Investor profile | Builders Republic
About
Jeito Capital is a leading venture capital firm dedicated to the biopharma sector. Founded by Dr. Rafaèle Tordjman (MD, PhD), Jeito stands out with a "patient benefit" driven approach. Unlike typical VCs that might exit early, Jeito operates on a model of "continuity," providing massive capital support from early clinical stages all the way to market access and commercialization. Their goal is to build the next generation of market leaders in medical innovation without them having to sell out too early to big pharma.
Key facts
- Type
- Venture Capital
- Stages
- Series A,Series B,Growth
- Sectors
- Biotech
- Headquarters
- France
- Offices
- Paris
- Geographic focus
- France,Europe,USA
- Lead / Follow
- Lead / co-lead
- Ticket size
- 10M€ – 50M€
- Assets under management
- 534M€
- Founded
- 2018
Track record
- Portfolio companies: 20
- Total investments: 29
- Exits: 3
Notable investments in France
Sparing Vision, Alentis Therapeutics, Eye Bio, Catalym
Key differentiators
Sector Specialist,Strong Track Record,Women-Led